Skip to main content
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • Special Issues
    • Archive
  • Topics
    • Applied and Environmental Science
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Novel Systems Biology Techniques
    • Early-Career Systems Microbiology Perspectives
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics
  • About the Journal
    • About mSystems
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM Journals
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mSystems
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • Special Issues
    • Archive
  • Topics
    • Applied and Environmental Science
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Novel Systems Biology Techniques
    • Early-Career Systems Microbiology Perspectives
  • For Authors
    • Getting Started
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics
  • About the Journal
    • About mSystems
    • Editor in Chief
    • Board of Editors
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Research Article | Molecular Biology and Physiology

Chemogenomic Screen for Imipenem Resistance in Gram-Negative Bacteria

Jessica Y. El Khoury, Alexandra Maure, Hélène Gingras, Philippe Leprohon, Marc Ouellette
Zackery Bulman, Editor
Jessica Y. El Khoury
Axe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Maure
Axe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hélène Gingras
Axe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Leprohon
Axe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Ouellette
Axe des Maladies Infectieuses et Immunitaires du Centre de Recherche du CHU de Québec and Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zackery Bulman
University of Illinois at Chicago
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/mSystems.00465-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Carbapenem-resistant Gram-negative bacteria are considered a major threat to global health. Imipenem (IMP) is used as a last line of treatment against these pathogens, but its efficacy is diminished by the emergence of resistance. We applied a whole-genome screen in Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolates that were submitted to chemical mutagenesis, selected for IMP resistance, and characterized by next-generation sequencing. A comparative analysis of IMP-resistant clones showed that most of the highly mutated genes shared by the three species encoded proteins involved in transcription or signal transduction. Of these, the rpoD gene was one of the most prevalent and an E. coli strain disrupted for rpoD displayed a 4-fold increase in resistance to IMP. E. coli and K. pneumoniae also specifically shared several mutated genes, most involved in membrane/cell envelope biogenesis, and the contribution in IMP susceptibility was experimentally proven for amidases, transferases, and transglycosidases. P. aeruginosa differed from the two Enterobacteriaceae isolates with two different resistance mechanisms, with one involving mutations in the oprD porin or, alternatively, in two-component systems. Our chemogenomic screen performed with the three species has highlighted shared and species-specific responses to IMP.

IMPORTANCE Gram-negative carbapenem-resistant bacteria are a major threat to global health. The use of genome-wide screening approaches to probe for genes or mutations enabling resistance can lead to identification of molecular markers for diagnostics applications. We describe an approach called Mut-Seq that couples chemical mutagenesis and next-generation sequencing for studying resistance to imipenem in the Gram-negative bacteria Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The use of this approach highlighted shared and species-specific responses, and the role in resistance of a number of genes involved in membrane biogenesis, transcription, and signal transduction was functionally validated. Interestingly, some of the genes identified were previously considered promising therapeutic targets. Our genome-wide screen has the potential to be extended outside drug resistance studies and expanded to other organisms.

INTRODUCTION

The World Health Organization (WHO) refers to antimicrobial resistance (AMR) as a major threat to global health and has established a list of priority pathogens for research and development of new effective antibiotics (1). Among the urgent threats is carbapenem resistance in the Gram-negative species Escherichia coli and Klebsiella pneumoniae. Both are commensal bacteria of the gastrointestinal tract of human and animals; they harbor many virulence factors and are responsible for different types of infections (2, 3). Another threat is represented by the opportunistic pathogen Pseudomonas aeruginosa (4). Those three bacterial species are leading causes of hospital-acquired infections (5).

Carbapenems such as imipenem (IMP) and meropenem (MEM) are β-lactam antibiotics (6) that bind and inhibit multiple penicillin binding proteins (PBPs) while resisting hydrolysis by class A extended-spectrum β-lactamases and class C β-lactamases (AmpC) (7). Carbapenems are used as a last line of treatment against multidrug-resistant Gram-negative pathogens (7). Nonetheless, resistance against carbapenems has been detected in Enterobacteriaceae mainly due to the production of more-potent β-lactamases such as K. pneumoniae carbapenemases (KPCs), class B metallo-β-lactamases (e.g., VIM, NDM, and IMP) and class D (OXA-type) β-lactamases found both on plasmids and in the chromosome (2, 8). Resistance resulting from the loss or modification of porins (OmpK35/36 for K. pneumoniae and OmpC/F for E. coli), in combination with the production of plasmid-encoded or chromosomally encoded AmpC, was also observed (9–12). The loss of the porin OprD in P. aeruginosa constitutes the major driver of carbapenem resistance, although resistance due to class B metallo-β-lactamases was also reported (13–16). β-lactam and β-lactamase inhibitor combinations (e.g., IMP-relebactam, MEM-vaborbactam) are showing promising results in vitro and in clinical trials against carbapenem-resistant Gram-negative bacteria (7, 17, 18). Both IMP and MEM target PBPs, and usually high-level resistance to IMP correlates with decreased susceptibility to MEM (19, 20). Studies performed with IMP have been useful for understanding the mode of action and resistance to carbapenems.

Exploring resistance to antibiotics at the genomic level is proving useful at revealing drug targets and modes of action, resistance mechanisms, and genes or mechanisms that play subtler roles such as facilitating resistance or compensating for fitness cost (21–24). The objective of this study was to apply a whole-genome sequencing (WGS) screen for IMP resistance in sensitive isolates of E. coli, K. pneumoniae, and P. aeruginosa. This screen couples chemical mutagenesis, selection for IMP resistance, and the characterization of IMP-resistant clones by next-generation sequencing (NGS). This approach, called “Mut-Seq” (25), has been helpful for various studies, including studies of drug resistance (26, 27). We found that the rpoD gene, encoding an RNA polymerase sigma factor, was the most prevalent mutated gene among IMP-resistant clones from the three species, and we experimentally validated its role in IMP resistance in E. coli. Mutations were also detected in several genes related to the cell wall and membrane biogenesis, and these are shown to confer low-level IMP resistance in Enterobacteriaceae. Finally, mutations in OprD were frequent in P. aeruginosa but we show that two-component (TC) signal transduction systems are also likely involved in IMP resistance.

RESULTS

Chemical mutagenesis and selection for resistance to IMP.E. coli ATCC 25922, K. pneumoniae ATCC 13883, and P. aeruginosa ATCC 27853 were treated with ethyl methane sulfonate (EMS) and selected for growth in the presence of IMP. The EMS concentrations and exposure and recovery times as well as the IMP concentrations for selection were optimized (see Materials and Methods). The minimum concentration of IMP used for selection was determined as the concentration at which growth occurred in the presence of IMP for the mutagenized populations but not for the nonmutagenized control populations.

The IMP-resistant clones for the three species were between 2-fold and 16-fold more resistant than the respective parental wild-type (WT) clones (Tables 1 and 2; see also Table S1 in the supplemental material). The levels of resistance to IMP measured for most clones of E. coli and K. pneumoniae were considered intermediate (MIC, 2 μg/ml) according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (28). The IMP MIC for two E. coli clones and five K. pneumoniae clones was 4 μg/ml, a level consistent with clinical resistance (Table 1 and Table S1, respectively). According to the MIC breakpoints for P. aeruginosa, all but one clone reached resistance levels consistent with clinical resistance (MIC, ≥8 μg/ml) (Table 2). We observed that cells with higher IMP MICs also showed decreased susceptibilities to MEM (Table 3). The MEM MICs increased by 2-fold, 4-fold, and up to 16-fold in IMP-selected K. pneumoniae, E. coli, and P. aeruginosa, respectively (Table 3). The MEM resistance in P. aeruginosa reached levels consistent with clinical resistance.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

IMP MICs for E. coli ATCC 25922 mutants and amino acid substitutions detected in genes mutated in at least three mutants

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

IMP MICs for P. aeruginosa ATCC 27853 mutants and amino acid substitutions detected in genes mutated in two or more mutants

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 3

IMP and MEM MICs for some selected mutants of E. coli, K. pneumoniae, and P. aeruginosa

TABLE S1

IMP MICs for K. pneumoniae ATCC 13883 mutants and mutations in genes shared with E. coli mutants. Download Table S1, PDF file, 0.08 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

Clusters of orthologous groups of mutated proteins.The genomes of 145 IMP-resistant clones (45 K. pneumoniae, 50 E. coli, and 50 P. aeruginosa clones) were analyzed by NGS. The genomes of the parent WT strains were also sequenced. A total of 3,810 single nucleotide (nt) variants (SNVs) were identified in the E. coli mutants (Fig. 1A), with a majority of the clones having at least 40 SNVs (Table S2). In K. pneumoniae, 1,379 SNVs were detected (Fig. 1A), with an average of 22 mutations (range, 5 to 39) per genome (Table S3). In P. aeruginosa, 654 SNVs were identified (Fig. 1A), with an average of 10 mutations (range, 2 to 18) found per mutant (Table S4). SNVs were more prevalent in coding regions than in intergenic regions for all species, and nonsynonymous SNVs predominated among coding mutations (Fig. 1A). While we cannot exclude the possibility that some SNVs resulted from IMP selection alone, it is highly likely that most were instead genuinely induced by EMS treatment. First, resistant clones were obtained using experimental conditions optimized such that no clone would grow upon IMP selection if the culture was not initially mutagenized by EMS. Second, most SNVs consisted of G-to-A and C-to-T transitions (Fig. 1B), which is consistent with the mode of action of EMS (29), and these were widespread among the 145 mutants sequenced. Some small insertions and deletions (InDels) were also observed in coding regions, and these were more frequent in P. aeruginosa than in E. coli or K. pneumoniae (Fig. 1A).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Summary of number and type of mutations induced by EMS in the three bacterial species. (A and B) Number and type (A) as well as distribution (B) of mutations found in Mut-Seq mutants selected for IMP resistance in E. coli (blue), K. pneumoniae (orange), and P. aeruginosa (green). Syn, synonymous; Non Syn, nonsynonymous; Del, deletion; Ins, insertion; RNA, rRNA, tRNA, transfer-messenger RNA (tmRNA), and noncoding RNA (ncRNA) (inclusive); SNV, single nucleotide variant.

TABLE S2

E. coli mutants and their corresponding mutations. Download Table S2, XLSX file, 0.4 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

TABLE S3

K. pneumoniae mutants and their corresponding mutations. Download Table S3, XLSX file, 0.1 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

TABLE S4

P. aeruginosa mutants and their corresponding mutations. Download Table S4, XLSX file, 0.07 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

We hypothesized that functional recurrence among mutated genes between species or clones would help in pinpointing the mutations that are the most relevant to IMP resistance. To ease comparisons among the three species, we relied classification using the Clusters of Orthologous Groups of proteins (COGs). The COG database is composed of over 4,600 specific functional COG descriptions grouped into 26 general category letter associations (30). We initially focused on the part of the COG descriptions corresponding to the mutated genes common to the three species, then on those shared by at least two species, and finally on the genes that are species specific but that were mutated in a higher number of clones. Thirty-five functional COG descriptions were found in common among the three species (Table S5). A third of these belonged to two general categories: (i) transcription mechanisms (K) and (ii) signal transduction mechanisms (T) (Fig. 2). The rpoD gene was the most prevalent in the COG category transcription, with mutations detected in a total of 10 mutants in the three species (Table S5). A C58T transition occurred in rpoD for one mutant each of K. pneumoniae and P. aeruginosa, leading to G20S and E20K amino acid substitutions, respectively, while eight E. coli mutants harbored mutations leading to an A72V, A444V, A444T, or I457L substitution (Fig. 3A). Additional genes coding for DNA-binding transcriptional regulators, sensor histidine kinases (HK), major facilitator superfamily transporters, and multidrug transporters were also mutated in the three species, but the mutations were often seen in a single mutant for each species and thus they were not further studied (Table S5).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

COG functional categories detected among the three species for the mutated genes. Mutated genes were classified into the appropriate COG, and the most common COGs shared by E. coli (blue), K. pneumoniae (orange), and P. aeruginosa (green) are shown.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Validation of the role of RpoD in IMP susceptibility. (A) Schematic representation of the RpoD (DR76_1419) domains. The mutation marked in red was used to generate the single knock-in in E. coli ATCC 25922 (rpoDG1331A::kan). Numbers between parentheses indicate the recurrence of the mutation among clones. The G20S and E20K (not shown) substitutions were found in only one mutant of K. pneumoniae and one of P. aeruginosa, respectively. σ70_r, sigma 70_region; ner, nonessential region. (B) Growth curves of rpoDWT::kan and rpoDG1331A::kan in LB in the absence or presence of IMP at the indicated concentrations. Data shown represent averages ± standard errors of the means (SEM) of results from three biological replicates done in technical triplicate. (C) Cultures of E. coli ATCC 25922 WT, rpoDWT::kan, and rpoDG1331A::kan were serially diluted and spotted on LB agar plates in the absence (-) or presence of imipenem (IMP) at the indicated concentrations. Plates were incubated overnight at 37°C and photographed. Data shown are representative of results from three biological replicates.

TABLE S5

Common COGs amongst the three species. Download Table S5, XLSX file, 0.03 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

The E. coli and K. pneumoniae mutants shared 275 COG descriptions. Of these, 11 consisted of one-to-one matches of E. coli and K. pneumoniae proteins that shared at least 70% sequence identity (implying genuine functional similarity) and that were also mutated in at least two mutants in each species (Table 4). These 11 genes belonged to 7 general functional categories, the cell wall/membrane/envelope biogenesis category (M) being the most prevalent, with 4 mutated genes (Table 4). One of the 11 genes was amiC coding for an N-acetylmuramoyl-l-alanine amidase mutated in 9 E. coli and 26 K. pneumoniae mutants (Table 4). A majority of mutations localized to the AmiC domain of the protein, and several were nonsense mutations (see Fig. S1A in the supplemental material). Another gene was nlpD, mutated in 5 E. coli and 18 K. pneumoniae mutants (Table 4). This gene codes for the activator of AmiC (31). Similarly to amiC, several nonsense mutations were observed in nlpD (Fig. S1B). The third gene was wecA, coding for an undecaprenyl-phosphate alpha-N-acetylglucosaminyl 1-phosphate transferase mutated in 5 mutants of each species (Table 4). The last gene from the M category was slt, which codes for a soluble lytic murein transglycosylase. The slt gene was mutated in 5 mutants, a majority harboring nonsense mutations (Fig. S1C). The remaining 7 genes were not part of the cell wall biogenesis category and had unrelated functions (Table 4). These were shared by 4 to 9 E. coli and K. pneumoniae mutants (Table 4). For gene clbJ (COG1020, category Q), the E1684G mutation found in 15 mutants of K. pneumoniae was present also in the IMP-sensitive E. coli WT strain, making it less likely to contribute to IMP resistance.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 4

COG categories and functional descriptions of genes mutated in at least two mutants of E. coli and K. pneumoniae

FIG S1

Schematic presentation of the domains of AmiC (A), NlpD (B), and Slt (C) and their respective mutations in E. coli (EC) and K. pneumoniae (KP). The Pfam protein family database was used to determine the domains of each protein, and DOG2.0 software was used for the visualization of the protein domain structures. Mutations marked in red are the mutations used to generate the single knock-in. Numbers between parentheses indicate the rate of recurrence of the mutations occurring two or more times. For Slt (C), the scheme represents the proteins in E. coli (EC) (121 Ins, W455*, and R475*) and K. pneumoniae (KP) (A152V and R376*). Download FIG S1, TIF file, 0.9 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

P. aeruginosa mutants were fairly distinct compared to E. coli and K. pneumoniae mutants, and these were thus not directly compared to E. coli and K. pneumoniae mutants in 2-way comparisons.

Species-specific mutations.Recurrence among clones was previously shown to ease the identification of SNVs contributing to the resistance phenotype (26), so, to retrieve gene candidates specifically mutated in E. coli, we thus focused on those mutated in at least 3 clones (Table 1). The gene yceG encoding a cell division protein was the most prevalent among E. coli clones, with 15 SNVs (including 5 nonsense mutations) detected in 20 mutants (Table 1). The second most prevalent gene was DR76_2948 coding for a trehalose-6-phosphate synthase, with two mutations (D376N and P380L) found in a total of 14 E. coli mutants (Table 1). Seven different mutations (5 of which were nonsense) occurred in the rne gene for six mutants. This gene codes for RNase E. Four different mutations occurred in five mutants for gene DR76_475, encoding a glutamate racemase. Finally, the tolA gene, which is part of the Tol-Pal cell envelope complex, was mutated in three E. coli mutants, including mutants M24 and M45, which also hold a mutated amiC gene (Table 1). A more exhaustive list of mutations can be found in Table S6.

TABLE S6

Common mutated genes amongst E. coli mutants. Download Table S6, XLSX file, 0.2 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

The mutational landscape of P. aeruginosa was more limited than that determined for E. coli (Fig. 1A), so we lowered our cutoff for candidate genes to correspond to those mutated in at least two mutants (Table S7). All mutants had a mutation either in the porin OprD or in two-component systems (TCSs) consisting of a sensor HK and a response regulator (Table 2). For oprD, 20 different mutations were found in 28 P. aeruginosa clones, 16 of which led to a stop codon (Table 2). Every mutant with a nonsense mutation in oprD had an IMP MIC of 16 μg/ml, representing an 8-fold increase compared to WT P. aeruginosa (Table 2). This was also the case for mutant M34 harboring a Y343N substitution in OprD, while other oprD coding mutations (G183D, G402D, and S325F) were associated with lower IMP resistance levels (Table 2). For TCSs, 15 mutants had a mutation in the sensor HK A4W92_13070 (Table 2). This HK is part of a two-component signal transduction system for which A4W92_13065, mutated in 4 independent P. aeruginosa clones (Table 2), is the response regulator. Interestingly, mutants M6 and M9 had a R419H mutation in the HK A4W92_04840 (Table 2), the same change that occurred in mutants M1, M3, and M11 for the HK described above (A4W92_13070). Lastly, the sensor HK PhoQ (A4W92_05675) was mutated in P. aeruginosa clones M5 (Q258*) and M36 (E198K) (Table 2).

TABLE S7

Common mutated genes amongst P. aeruginosa mutants. Download Table S7, XLSX file, 0.02 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

Phenotypic validation of mutations highlighted by Mut-Seq.The role of specific mutations in resistance to IMP was tested in E. coli ATCC 25922 using a knock-in approach. This involved the transformation of WT cells with a DNA cassette made of a PCR fragment containing the mutation fused to a kanamycin (Kan) resistance gene flanked by FLP recombination target (FRT) sequences used for the removal of the selection marker by the FLP/FLPe recombinase. For the rpoD gene mutated in all species, we tested the G1331A transition that was detected in E. coli and that led to the A444V amino acid substitution (Table 5). This mutation conferred a 4-fold increase in IMP resistance in the rpoDG1331A::kan transformants compared to the rpoDWT::kan cells used as a control (we failed to remove the kan resistance marker in rpoDG1331A::kan despite several attempts) (Table 5). The transformant rpoDWT::kan had the same IMP MIC (0.25 μg/ml) as the E. coli ATCC 25922 WT. The A444V mutation allowed cells to sustain higher IMP concentrations than the control both in liquid medium (Fig. 3B) and on solid agar (Fig. 3C) but conferred a slight fitness cost in the absence of IMP (Fig. 3B). Interestingly, the rpoDG1331A::kan mutant had decreased susceptibility also for MEM (Table 5).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 5

Functional validation of mutation detected in E. coli IMP-resistant mutants

Using the same knock-in approach, we also investigated the role in IMP resistance of mutations in genes shared by E. coli and K. pneumoniae mutants (Table 4). The G402R substitution in AmiC, a position mutated in two E. coli mutants and one mutant of K. pneumoniae (Fig. S1A), decreased the susceptibility to IMP by 2-fold when introduced into E. coli ATCC 25922 (Table 5). Similarly, the nonsense mutations Q161* and R475* in NlpD and Slt, respectively, increased the IMP MIC by 2-fold (Table 5). E. coli mutant M14 and K. pneumoniae mutant M17 had mutations in both amiC and slt, and the AmiC G402R and Slt R475* mutations were indeed additive in increasing the IMP MIC by 4-fold under conditions of cotransformation into E. coli ATCC 25922 (Table 5). This amiC and slt double knock-in also showed decreased susceptibility to MEM (Table 5). Despite being mutated in 5 mutants each of E. coli and K. pneumoniae (Table 4), the role of wecA mutations was less clear as the transformant for the R40C mutation (detected in E. coli mutant M12) was not conclusively altered for its IMP MIC (Table 5). Regarding the mutations in genes that are unrelated to cell wall biogenesis but that have at least 70% sequence identity between E. coli and K. pneumoniae (Table 4), we tested mutations A138V in SpoT, A429T in DR76_3362, and A539V in GidA, but, similarly to the results seen with wecA, none had a significant impact on the IMP MIC (Table 5).

We also tested some representatives of the most prevalent genes specifically detected in E. coli. The mutations in yceG and rne leading to the Q92* and Q775* nonsense mutations, respectively, as well as the P380L substitution in DR76_2948 and the M67I mutation in TolA, were independently transformed in E. coli ATCC 25922. The IMP MIC was increased by 2-fold (0.5 μg/ml) in the case of the rne and tolA knock-in (Table 5).

The knock-ins for mutations in wecA and spoT described above had an ambiguous phenotype by MIC measurements, so we looked for subtler phenotypes by monitoring their growth by serial dilution on solid medium in the presence of IMP. As expected, the E. coli M14 mutant (harboring an A138V mutation in SpoT) grew until it reached the highest cell dilution and IMP concentration tested. In contrast, E. coli ATCC 25922 WT grew only to the 10−1 dilution on an agar plate supplemented with 0.25 μg/ml of IMP (its MIC) (Fig. 4). As a positive control for transformation, we used the M67I mutation in TolA. This mutation allowed cells to grow until they reached the 10−2 dilution at 0.5 μg/ml (Fig. 4), consistent with the MIC of this transformant (Table 5). Mutations R40C in WecA and A138V in SpoT had an intermediate phenotype in growing with more dilutions than the WT cells at 0.12 μg/ml IMP and at the 10−1 dilution at 0.25 μg/ml IMP (Fig. 4). Given its recurrence, we also tested the yceG gene but the Q92* mutation did not increase growth in the presence of IMP and was even detrimental under the conditions tested (Fig. 4).

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

Validation of the roles of WecA and SpoT in IMP susceptibility in E. coli. Cultures of E. coli ATCC 25922 WT; of single knock-ins harboring TolA (M67I), WecA (R40C), SpoT (A138V), or YceG (Q92*) mutations; and of E. coli IMP-resistant mutant M14 were serially diluted and spotted on LB agar plates in the absence (-) or presence of imipenem (IMP) at the indicated concentrations. Plates were incubated overnight at 37°C and photographed.

DISCUSSION

The use of whole-genome screens is now allowing holistic views of mechanisms of action and mechanisms of resistance against antimicrobial agents. We applied here a Mut-Seq screen (25, 26, 32) combining chemical mutagenesis and NGS to obtain clones of E. coli, K. pneumoniae, and P. aeruginosa with decreased susceptibility to IMP. The main advantage of Mut-Seq in comparison to other approaches such as step-by-step drug selection is the rapidity with which resistant mutants are obtained (24 h versus months), hence accelerating studies on the mode of action or mechanisms of resistance to antimicrobials. We posited that using diverse species and analyzing a large set of independent mutants would pinpoint shared pathways of resistance as well as species-specific traits. As expected from phylogeny, the response of E. coli to IMP shared more similarity with K. pneumoniae than with P. aeruginosa. Some responses were shared among the three species, and while we concentrated on the genes mutated in the greatest number of mutants, it is quite possible that mutant-specific genes are also important for IMP responses.

The two main categories of orthologous proteins shared among the three species were those corresponding to transcription and signal transduction mechanisms. The most prevalent gene common to the three species was rpoD, which codes for the σ70 factor that is associated with the core RNA polymerase complex for initiation of specific transcription (33). Mutations in rpoD were in distinct domains, and we validated experimentally the role of the A444V substitution detected in several independent E. coli mutants. This substitution occurred in a region of RpoD that is highly conserved, as it is part of the −10 promoter recognition helix binding (34). One current limitation of our work is the lack of validation of the role of rpoD directly in K. pneumoniae or P. aeruginosa. This type of effort could form the basis of further studies. While rpoD has never been shown to be involved with IMP resistance, sigma factors are well known to regulate a number of genes often associated with responses to stress (35). Further work may also provide insights into the downstream target gene(s) responsible for the decrease in IMP susceptibility. Many other genes (62 in E. coli and 39 in K. pneumoniae), including several that are strain specific, that are involved in transcription were mutated, and some may indeed help in the response to IMP. Among many of the TCSs mutated in each of the three species, evgS and phoQ were common (see Table S5 in the supplemental material). Knock-in of evgS or phoQ was not possible because of the gene arrangement and the close proximity of their respective regulators evgA and phoP.

IMP inhibits bacterial cell wall synthesis by binding to and inactivating the PBPs, with the highest affinity to PBP-1a, PBP-1b, and PBP-2 (36, 37), leading to rapid cell lysis and death (38). MEM also targets PBPs, with the highest affinity for Pseudomonas PBP-2 and PBP-3. While less active than IMP against enterococci, it is more active against P. aeruginosa (39). Our highly IMP-resistant P. aeruginosa mutants and our E. coli knock-ins with at least 4-fold resistance to IMP were all less susceptible to MEM (Table 3 and Table 5), demonstrating that our findings with IMP can be applied to MEM as long as the IMP MIC has reached a minimum threshold. This corroborates results of other studies demonstrating that IMP-resistant P. aeruginosa strains are usually cross-resistant to MEM as well (19, 20). Similarly, E. coli strains selected for MEM resistance showed decreased susceptibility to IMP (40). Consistent with IMP mode of action, genes from the category of cell wall and membrane biogenesis were among those most highly represented in E. coli and K. pneumoniae. Amidases such as AmiC split the peptidoglycan (PG) of daughter cells during cell division (37). These amidases are autoinhibited and AmiC is activated by NlpD, a lipoprotein anchored in the outer membrane (31). Mutations in both amiC and nlpD contributed to a decrease in susceptibility to IMP (Table 5). It was demonstrated that the Tol-Pal system is implicated in regulating cell wall cleavage during cell division by activating NlpD (41) as well as in the modulation of PG synthesis (42). TolA, part of the Tol-Pal complex, was found mutated in three mutants of E. coli, and the M67I mutation decreased the susceptibility of the WT strain by 2-fold (Table 5). Mutations in amiC, nlpD, and tolA are likely to be loss-of-function mutations, since nlpD and amiC have nonsense mutations or InDels in many mutants (see Fig. S1A and B in the supplemental material). Our observations are consistent with previous studies where mutants lacking nlpD or amidases and several lytic transglycosylases (see below) displayed a delayed lysis response to ampicillin (43, 44).

The PG is made of alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) connected by a β-1,4-glycosidic bond (37). Lytic transglycosylases (LTs) cleave this glycosidic bond (37). E. coli has eight membrane-bound LTs (MLTs) and one soluble LT named Slt70 (37). Several of these LTs (MltA, MltB, MltD, and RlpA) were mutated in single E. coli or K. pneumoniae mutants and were not studied (Tables S2 and S3), but the yceG (MltG) gene was mutated in 20 E. coli mutants, including 5 with nonsense mutations (Table 1). The transformation of the mutation Q92* in the E. coli ATCC 25922 WT did not change the susceptibility of the strain to IMP, and it did not provide a growth advantage in the presence of IMP (Table 5) (Fig. 4). While we could not find a specific role of yceG in IMP resistance, its frequent mutation in E. coli suggests a role possibly in combination with other mutations. Indeed, MltG was shown to interact with PBP1b and in the absence of PBP1b, MltG was shown to be toxic (45). Since IMP inhibits PBP1b, it is possible that loss-of-function mutations in yceG are selected to limit its toxicity. Inhibition of PBPs by β-lactams leads to an accumulation of non-cross-linked PG, and Slt70 is the main enzyme responsible for destroying this nascent PG (46). Slt inactivation produced differential effects on β-lactam sensitivity depending on the genetic background (46–48). Here, we showed that a slt nonsense mutation (R475*) in E. coli ATCC 25922 decreased the susceptibility to IMP by 2-fold.

The response of P. aeruginosa to IMP differed extensively from the responses seen with the two Enterobacteriaceae species. The outer membrane permeability of P. aeruginosa is about 12-to-100-fold lower than that of E. coli (49), and this is probably due to a reduced number of general diffusion porins and the presence of a variety of specific porins such as OprD (16, 50). IMP penetrates the pseudomonal membrane through OprD (51). Resistance to IMP in P. aeruginosa can occur through loss of OprD, which has been reported to take place at the levels of transcription and translation (14, 52). Mutations resulting in a premature stop codon were found in a number of clinical isolates (53–56), several of which (W6*, Q19*, W65*, W138*, Q158*, W277*, Q295*, W339*, and W415*) were also detected in this study together with new ones (Q30*, Q67*, Q79*, and Q235*) (Table 2). Stop codons occurred at tryptophan or glutamine residues, representing the only two codons that can be changed to a stop codon through a single transition (along with one of the six codons for arginine) induced by EMS. TCSs are known to downregulate OprD and contribute to IMP resistance (57, 58). Among the P. aeruginosa ATCC 27853 mutants selected in this study, 19 mutants had a mutation either in the sensor HK gene (A4W92_13070) or in the gene encoding its response regulator (A4W92_13065) without having a mutated oprD gene (Table 2). Two independent mutants had a mutation in another sensor HK gene (A4W92_04840) (Table 2). These mutated HKs belong to the same clade as the ones known to regulate OprD (59). Two mutations (E198K and Q258*) in the sensor HK PhoQ (A4W92_05675) were detected in two independent clones (Table 2). A PhoQ-null mutant is resistant to polymyxin B and to aminoglycoside antibiotics (60–62), and PhoQ mutants were reported in P. aeruginosa clinical isolates resistant to polymyxin B (63) or colistin (polymyxin E) (64). Current understanding would suggest that the mutated HKs activate their respective response regulators and that they in turn downregulate oprD. Mutated HKs were also observed in E. coli and K. pneumoniae strains resistant to IMP (Table S5), highlighting the potential key role of HKs in IMP responses in Gram-negative bacteria.

Our chemogenomic screen performed with three bacterial species highlighted shared and species-specific responses to IMP. The most highly mutated genes encoded proteins involved in transcription, signal transduction, and membrane/cell envelope biogenesis. The number of mutants investigated allowed a holistic view of the response to IMP and enabled concentrating our functional work on the most frequently recurrent genes. Most mutations tested in E. coli were associated with a 2-fold difference in IMP susceptibility. This relatively low level of resistance may reflect more-subtle roles for the mutations, such as facilitating resistance emergence or compensating for fitness cost. Many other mutations are likely to be involved in response to IMP, and our data set can be useful to better understand IMP and to find strategies to restore carbapenem susceptibility in Gram-negative bacteria.

MATERIALS AND METHODS

Bacterial strains, plasmids, and growth conditions.Bacterial strains and plasmids used in this study are listed in Table S8 in the supplemental material. Unless otherwise specified, E. coli (ATCC 25922), K. pneumoniae (ATCC 13883), and P. aeruginosa (ATCC 27853) were cultured on Luria-Bertani (LB) or nutrient agar (1.5%) and incubated at 37°C for 18 to 24 h. Liquid cultures were grown in LB for E. coli and in brain heart infusion (BHI) medium for K. pneumoniae and P. aeruginosa. Plasmid pRedET and the FRT-flanked PGK-gb2-kan cassette (catalogue number K006) and the enhanced FLP expression plasmid 707-FLPe (catalogue number A104) with a tetracycline resistance marker were obtained from Gene Bridges GmbH. IMP-monohydrate and MEM were purchased from Santa Cruz Biotechnology; all other chemicals were purchased from Sigma-Aldrich.

TABLE S8

Strains and plasmids used in this study and primers used to generate the single knock-in and the double knock-in. Download Table S8, PDF file, 0.03 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

Antibacterial susceptibility testing.Analyses of the IMP or MEM MICs for the WT strain of each of the three species and for their respective mutants and optimization of the EMS concentrations (Table S8) were performed by microdilution in 96-well plates according to recommendations from the CLSI. The IMP or MEM MICs for the single or double knock-ins were determined by macrodilution. All MICs were determined from at least three independent biological replicates, each replicate being further assessed in technical duplicates.

Chemical mutagenesis and selection of antibiotic-resistant mutants.Optimization was performed by testing different concentrations of EMS equivalent to 4×, 8×, or 16× its MIC for each of the three species for either 10 or 20 min. We selected conditions that allowed treated cells to reach an optical density at 600 nm (OD600) of 0.5 in less than 6 h. For K. pneumoniae and P. aeruginosa, this represented an EMS concentration equivalent to 4 times their MIC (0.024 g/ml and 0.012 g/ml, respectively) maintained for 10 min. For E. coli, we used an EMS concentration equivalent to 8 times its MIC (0.048 g/ml) maintained for 20 min. The minimum concentration of IMP used for selection was determined as the concentration at which growth occurred in the presence of IMP for the mutagenized populations but not for the nonmutagenized control populations. This represented IMP concentrations equivalent to 16× and 20× the MIC in the case of E. coli (4 and 5 μg/ml) and between 2× and 4× the MIC for both K. pneumoniae (2 and 4 μg/ml) and P. aeruginosa (4 and 8 μg/ml). No clones survived beyond these concentrations. The detailed protocol was as follows: the overnight (ON) cultures of the strains were diluted and incubated at 37°C with shaking (220 rpm) until they reached an OD600 of 0.5. Each culture was separated into two tubes of 10 ml. We added EMS to one of the tubes at the appropriate concentration. Cultures were incubated for 10 min (K. pneumoniae and P. aeruginosa) or 20 min (E. coli) at 37°C. Cultures were then diluted by half using ice-cold medium and then further diluted by 1/10 before being incubated until an OD600 of 0.5 was reached. The cultures were centrifuged at 4,000 rpm for 5 min, and then the pellet was resuspended in 200 μl of the culture medium. Ten-fold dilutions (from 10−3 to 10−7) were spread on agar plates to allow colony counting.

In order to select mutants resistant to IMP, 100-μl volumes of the mutagenized cultures were spread on agar plates containing an increasing concentration of the antibiotic (between 2× and 20× the MIC depending on the species). Agar plates were incubated overnight at 37°C, and colonies were counted the next day. This protocol was performed for each strain in duplicate.

Extraction and quantification of DNA.Genomic DNA (gDNA) was extracted using a Wizard Genomic DNA purification kit (Promega) according to the manufacturer’s protocol. The purity of the gDNA was analyzed using a NanoDrop spectrophotometer. Quantification was performed by fluorescence detection using a QuantiFluor One double-stranded DNA (dsDNA) system (Promega).

DNA sequencing.Libraries were produced from 0.8 ng of gDNA using a Nextera XT DNA Library Prep kit (Illumina) according to the manufacturer’s protocol. Libraries were verified by the use of model 2100 Bioanalyzer high-sensitivity DNA chips (Agilent) and quantified by the use of a QuantiFluor One dsDNA system (Promega). Libraries were sequenced on an Illumina HiSeq 2500 system (101-nt paired-end sequencing) at a final concentration of 8 pM.

Mut-Seq data analysis.Sequence reads were aligned to the E. coli ATCC 25922 (BioProject accession no. PRJNA244551), K. pneumoniae ATCC 13883 (PRJNA244567), and P. aeruginosa ATCC 27853 (PRJNA316664) genomes using bwa-mem software (65). The seed length was 32, and 2 mismatches were allowed within the seed; the maximum number of mismatches allowed was 4. Read duplicates were marked using Picard (http://broadinstitute.github.io/picard/), and calling of SNVs and InDels was done using GATK software (66). Mutations in common with the WT strain sequence examined in parallel were excluded, and the remaining mutations (i.e., mutant-specific mutations) were annotated. To ease the comparisons among the three species, the common COGs (30) were determined using the workflow of COGsoft (https://sourceforge.net/projects/cogtriangles/files/).

Generation of knock-ins in E. coli.We first transformed E. coli ATCC 25922 with the expression plasmid pRedET as recommended by the manufacturer (Gene Bridges GmbH). Mutated PCR fragments of the genes of interest were amplified from the appropriate E. coli mutant and fused to the FRT-flanked PGK-gb2-kan cassette before being transformed in the E. coli strain containing the pRedEt plasmid. This strategy was previously described by Sukhija et al. and Pyne et al. (67, 68). l-Arabinose was added to induce the expression of the Red/ET recombination proteins, and transformants were selected with Kan (40 μg/ml). Colonies were analyzed by colony PCR and sequencing. All primers used to generate the single knock-ins and to check the right integration of the gene replacement cassette are listed in Table S8. The enhanced FLP conditional expression plasmid 707-FLPe was transformed into the strain containing the gene replacement cassette so that recombination would occur at the FRT sites. PCR was used to confirm both the removal of the Kan cassette by FLP recombination and the presence of the knock-in mutation.

Testing the effect of mutations on the growth of E. coli.Cultures (OD600 = 0.9) were serially diluted (10−1 to 10−6) in LB, and 5-μl volumes were spotted on freshly prepared LB agar plates supplemented with different concentrations of IMP. Plates were incubated at 37°C overnight, and they were photographed the next day using an AlphaImager system (Alpha Innotech).

For determination of the growth curve in liquid medium, 5 μl of 1 × 107 CFU/ml was inoculated in 200 μl of LB medium in the absence or presence of IMP at concentrations of 0.03 to 4 μg/ml in 96-well plates. The plate was incubated at 37°C, and the OD600 was read each 30 min after shaking for 10 s using a Cytation 5 multimode reader. Each assay was done in technical triplicate and biological triplicate.

Data availability.The WGS data have been deposited in the SRA database, and the accession numbers are listed in Table S9.

TABLE S9

Accession numbers of E. coli, K. pneumoniae, and P. aeruginosa mutants in the SRA database. Download Table S9, XLSX file, 0.02 MB.
Copyright © 2019 El Khoury et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

ACKNOWLEDGMENTS

We thank Michel G. Bergeron for providing bacterial strains ATCC 13883 and ATCC 27853.

This work was supported by the Canadian Institutes of Health Research Foundation (grant FDN 167283 to M.O.). M.O. is the holder of a Tier a Canada Research Chair in Antimicrobial Resistance. We declare that we have no conflicts of interest.

J.Y.E.K. designed and performed the experiments, analyzed the data, and drafted the manuscript. A.M. and H.G. were involved in the design of Mut-Seq and with experiments. P.L. provided the bioinformatics pipeline for the Mut-Seq analysis and revised the manuscript. M.O. supervised the work and revised the manuscript.

FOOTNOTES

    • Received July 31, 2019.
    • Accepted November 6, 2019.
  • Copyright © 2019 El Khoury et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Tacconelli E,
    2. Carrara E,
    3. Savoldi A,
    4. Harbarth S,
    5. Mendelson M,
    6. Monnet DL,
    7. Pulcini C,
    8. Kahlmeter G,
    9. Kluytmans J,
    10. Carmeli Y,
    11. Ouellette M,
    12. Outterson K,
    13. Patel J,
    14. Cavaleri M,
    15. Cox EM,
    16. Houchens CR,
    17. Grayson ML,
    18. Hansen P,
    19. Singh N,
    20. Theuretzbacher U,
    21. Magrini N
    . 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. doi:10.1016/S1473-3099(17)30753-3.
    OpenUrlCrossRef
  2. 2.↵
    1. Nordmann P,
    2. Dortet L,
    3. Poirel L
    . 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18:263–272. doi:10.1016/j.molmed.2012.03.003.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Navon-Venezia S,
    2. Kondratyeva K,
    3. Carattoli A
    . 2017. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 41:252–275. doi:10.1093/femsre/fux013.
    OpenUrlCrossRef
  4. 4.↵
    1. López-Causapé C,
    2. Cabot G,
    3. Del Barrio-Tofiño E,
    4. Oliver A
    . 2018. The versatile mutational resistome of Pseudomonas aeruginosa. Front Microbiol 9:685. doi:10.3389/fmicb.2018.00685.
    OpenUrlCrossRef
  5. 5.↵
    1. Peleg AY,
    2. Hooper DC
    . 2010. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362:1804–1813. doi:10.1056/NEJMra0904124.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Papp-Wallace KM,
    2. Endimiani A,
    3. Taracila MA,
    4. Bonomo RA
    . 2011. Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943–4960. doi:10.1128/AAC.00296-11.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Lob SH,
    2. Hackel MA,
    3. Kazmierczak KM,
    4. Young K,
    5. Motyl MR,
    6. Karlowsky JA,
    7. Sahm DF
    . 24 May 2017, posting date. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART Global Surveillance Program). Antimicrob Agents Chemother doi:10.1128/AAC.02209-16.
    OpenUrlCrossRef
  8. 8.↵
    1. Diene SM,
    2. Rolain JM
    . 2014. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas, and Acinetobacter species. Clin Microbiol Infect 20:831–838. doi:10.1111/1469-0691.12655.
    OpenUrlCrossRef
  9. 9.↵
    1. Bidet P,
    2. Burghoffer B,
    3. Gautier V,
    4. Brahimi N,
    5. Mariani-Kurkdjian P,
    6. El-Ghoneimi A,
    7. Bingen E,
    8. Arlet G
    . 2005. In vivo transfer of plasmid-encoded ACC-1 AmpC from Klebsiella pneumoniae to Escherichia coli in an infant and selection of impermeability to imipenem in K. pneumoniae. Antimicrob Agents Chemother 49:3562–3565. doi:10.1128/AAC.49.8.3562-3565.2005.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Queenan AM,
    2. Bush K
    . 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458. doi:10.1128/CMR.00001-07.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Chia JH,
    2. Siu LK,
    3. Su LH,
    4. Lin HS,
    5. Kuo AJ,
    6. Lee MH,
    7. Wu TL
    . 2009. Emergence of carbapenem-resistant Escherichia coli in Taiwan: resistance due to combined CMY-2 production and porin deficiency. J Chemother 21:621–626. doi:10.1179/joc.2009.21.6.621.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Shin SY,
    2. Bae IK,
    3. Kim J,
    4. Jeong SH,
    5. Yong D,
    6. Kim JM,
    7. Lee K
    . 2012. Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36. J Med Microbiol 61:239–245. doi:10.1099/jmm.0.037036-0.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Rodriguez-Martinez JM,
    2. Poirel L,
    3. Nordmann P
    . 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:4783–4788. doi:10.1128/AAC.00574-09.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Fang ZL,
    2. Zhang LY,
    3. Huang YM,
    4. Qing Y,
    5. Cao KY,
    6. Tian GB,
    7. Huang X
    . 2014. OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China. Infect Genet Evol 21:124–128. doi:10.1016/j.meegid.2013.10.027.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hong DJ,
    2. Bae IK,
    3. Jang IH,
    4. Jeong SH,
    5. Kang HK,
    6. Lee K
    . 2015. Epidemiology and characteristics of metallo-beta-lactamase-producing Pseudomonas aeruginosa. Infect Chemother 47:81–97. doi:10.3947/ic.2015.47.2.81.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Pang Z,
    2. Raudonis R,
    3. Glick BR,
    4. Lin TJ,
    5. Cheng Z
    . 2019. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37:177–192. doi:10.1016/j.biotechadv.2018.11.013.
    OpenUrlCrossRef
  17. 17.↵
    1. Zhanel GG,
    2. Lawrence CK,
    3. Adam H,
    4. Schweizer F,
    5. Zelenitsky S,
    6. Zhanel M,
    7. Lagace-Wiens PRS,
    8. Walkty A,
    9. Denisuik A,
    10. Golden A,
    11. Gin AS,
    12. Hoban DJ,
    13. Lynch JP, III,
    14. Karlowsky JA
    . 2018. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs 78:65–98. doi:10.1007/s40265-017-0851-9.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Schmidt-Malan SM,
    2. Mishra AJ,
    3. Mushtaq A,
    4. Brinkman CL,
    5. Patel R
    . 27 July 2018, posting date. In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant Gram-negative bacilli. Antimicrob Agents Chemother doi:10.1128/AAC.00533-18.
    OpenUrlCrossRef
  19. 19.↵
    1. Livermore DM,
    2. Yang YJ
    . 1989. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. J Antimicrob Chemother 24(Suppl A):149–159. doi:10.1093/jac/24.suppl_a.149.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Voutsinas D,
    2. Mavroudis T,
    3. Avlamis A,
    4. Giamarellou H
    . 1989. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. J Antimicrob Chemother 24(Suppl A):143–147. doi:10.1093/jac/24.suppl_a.143.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Feng J,
    2. Lupien A,
    3. Gingras H,
    4. Wasserscheid J,
    5. Dewar K,
    6. Legare D,
    7. Ouellette M
    . 2009. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19:1214–1223. doi:10.1101/gr.089342.108.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Fani F,
    2. Leprohon P,
    3. Legare D,
    4. Ouellette M
    . 2011. Whole genome sequencing of penicillin-resistant Streptococcus pneumoniae reveals mutations in penicillin-binding proteins and in a putative iron permease. Genome Biol 12:R115. doi:10.1186/gb-2011-12-11-r115.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Koser CU,
    2. Ellington MJ,
    3. Peacock SJ
    . 2014. Whole-genome sequencing to control antimicrobial resistance. Trends Genet 30:401–407. doi:10.1016/j.tig.2014.07.003.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Rimoldi SG,
    2. Gentile B,
    3. Pagani C,
    4. Di Gregorio A,
    5. Anselmo A,
    6. Palozzi AM,
    7. Fortunato A,
    8. Pittiglio V,
    9. Ridolfo AL,
    10. Gismondo MR,
    11. Rizzardini G,
    12. Lista F
    . 2017. Whole genome sequencing for the molecular characterization of carbapenem-resistant Klebsiella pneumoniae strains isolated at the Italian ASST Fatebenefratelli Sacco Hospital, 2012–2014. BMC Infect Dis 17:666. doi:10.1186/s12879-017-2760-7.
    OpenUrlCrossRef
  25. 25.↵
    1. Robins WP,
    2. Faruque SM,
    3. Mekalanos JJ
    . 2013. Coupling mutagenesis and parallel deep sequencing to probe essential residues in a genome or gene. Proc Natl Acad Sci U S A 110:E848–E857. doi:10.1073/pnas.1222538110.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Gingras H,
    2. Patron K,
    3. Bhattacharya A,
    4. Leprohon P,
    5. Ouellette M
    . 25 April 2019, posting date. Gain and loss of function screens coupled to next generation sequencing for antibiotic mode of action and resistance studies in Streptococcus pneumoniae. Antimicrob Agents Chemother doi:10.1128/AAC.02381-18.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Brammeld JS,
    2. Petljak M,
    3. Martincorena I,
    4. Williams SP,
    5. Alonso LG,
    6. Dalmases A,
    7. Bellosillo B,
    8. Robles-Espinoza CD,
    9. Price S,
    10. Barthorpe S,
    11. Tarpey P,
    12. Alifrangis C,
    13. Bignell G,
    14. Vidal J,
    15. Young J,
    16. Stebbings L,
    17. Beal K,
    18. Stratton MR,
    19. Saez-Rodriguez J,
    20. Garnett M,
    21. Montagut C,
    22. Iorio F,
    23. McDermott U
    . 2017. Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Res 27:613–625. doi:10.1101/gr.213546.116.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Wayne P
    . 2019. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
  29. 29.↵
    1. Du H,
    2. Pan B,
    3. Chen T
    . 2017. Evaluation of chemical mutagenicity using next generation sequencing: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 35:140–158. doi:10.1080/10590501.2017.1328831.
    OpenUrlCrossRef
  30. 30.↵
    1. Galperin MY,
    2. Makarova KS,
    3. Wolf YI,
    4. Koonin EV
    . 2015. Expanded microbial genome coverage and improved protein family annotation in the COG database. Nucleic Acids Res 43:D261–D269. doi:10.1093/nar/gku1223.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Peters NT,
    2. Dinh T,
    3. Bernhardt TG
    . 2011. A fail-safe mechanism in the septal ring assembly pathway generated by the sequential recruitment of cell separation amidases and their activators. J Bacteriol 193:4973–4983. doi:10.1128/JB.00316-11.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Lehrbach NJ,
    2. Ji F,
    3. Sadreyev R
    . 2017. Next-generation sequencing for identification of EMS-induced mutations in Caenorhabditis elegans. Curr Protoc Mol Biol 117:7.29.1–7 29.12. doi:10.1002/cpmb.27.
    OpenUrlCrossRef
  33. 33.↵
    1. Borukhov S,
    2. Nudler E
    . 2008. RNA polymerase: the vehicle of transcription. Trends Microbiol 16:126–134. doi:10.1016/j.tim.2007.12.006.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Campbell EA,
    2. Muzzin O,
    3. Chlenov M,
    4. Sun JL,
    5. Olson CA,
    6. Weinman O,
    7. Trester-Zedlitz ML,
    8. Darst SA
    . 2002. Structure of the bacterial RNA polymerase promoter specificity sigma subunit. Mol Cell 9:527–539. doi:10.1016/s1097-2765(02)00470-7.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Paget MS
    . 2015. Bacterial sigma factors and anti-sigma factors: structure, function and distribution. Biomolecules 5:1245–1265. doi:10.3390/biom5031245.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Sauvage E,
    2. Terrak M
    . 17 February 2016, posting date. Glycosyltransferases and transpeptidases/penicillin-binding proteins: valuable targets for new antibacterials. Antibiotics (Basel) doi:10.3390/antibiotics5010012.
    OpenUrlCrossRef
  37. 37.↵
    1. Dik DA,
    2. Fisher JF,
    3. Mobashery S
    . 2018. Cell-wall recycling of the Gram-negative bacteria and the nexus to antibiotic resistance. Chem Rev 118:5952–5984. doi:10.1021/acs.chemrev.8b00277.
    OpenUrlCrossRef
  38. 38.↵
    1. Rodloff AC,
    2. Goldstein EJ,
    3. Torres A
    . 2006. Two decades of imipenem therapy. J Antimicrob Chemother 58:916–929. doi:10.1093/jac/dkl354.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Edwards JR,
    2. Turner PJ
    . 1995. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis Suppl 96:5–10.
    OpenUrlPubMed
  40. 40.↵
    1. Adler M,
    2. Anjum M,
    3. Andersson DI,
    4. Sandegren L
    . 2016. Combinations of mutations in envZ, ftsI, mrdA, acrB and acrR can cause high-level carbapenem resistance in Escherichia coli. J Antimicrob Chemother 71:1188–1198. doi:10.1093/jac/dkv475.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Tsang MJ,
    2. Yakhnina AA,
    3. Bernhardt TG
    . 2017. NlpD links cell wall remodeling and outer membrane invagination during cytokinesis in Escherichia coli. PLoS Genet 13:e1006888. doi:10.1371/journal.pgen.1006888.
    OpenUrlCrossRef
  42. 42.↵
    1. Gray AN,
    2. Egan AJ,
    3. van't Veer IL,
    4. Verheul J,
    5. Colavin A,
    6. Koumoutsi A,
    7. Biboy J,
    8. Altelaar AFM,
    9. Damen MJ,
    10. Huang KC,
    11. Simorre J-P,
    12. Breukink E,
    13. den Blaauwen T,
    14. Typas A,
    15. Gross CA,
    16. Vollmer W
    . 7 May 2015, posting date. Coordination of peptidoglycan synthesis and outer membrane constriction during Escherichia coli cell division. Elife doi:10.7554/eLife.07118.
    OpenUrlCrossRef
  43. 43.↵
    1. Heidrich C,
    2. Ursinus A,
    3. Berger J,
    4. Schwarz H,
    5. Holtje JV
    . 2002. Effects of multiple deletions of murein hydrolases on viability, septum cleavage, and sensitivity to large toxic molecules in Escherichia coli. J Bacteriol 184:6093–6099. doi:10.1128/jb.184.22.6093-6099.2002.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Uehara T,
    2. Dinh T,
    3. Bernhardt TG
    . 2009. LytM-domain factors are required for daughter cell separation and rapid ampicillin-induced lysis in Escherichia coli. J Bacteriol 191:5094–5107. doi:10.1128/JB.00505-09.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Yunck R,
    2. Cho H,
    3. Bernhardt TG
    . 2016. Identification of MltG as a potential terminase for peptidoglycan polymerization in bacteria. Mol Microbiol 99:700–718. doi:10.1111/mmi.13258.
    OpenUrlCrossRef
  46. 46.↵
    1. Cho H,
    2. Uehara T,
    3. Bernhardt TG
    . 2014. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell 159:1300–1311. doi:10.1016/j.cell.2014.11.017.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Templin MF,
    2. Edwards DH,
    3. Holtje JV
    . 1992. A murein hydrolase is the specific target of bulgecin in Escherichia coli. J Biol Chem 267:20039–20043.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Costa CS,
    2. Anton DN
    . 2006. High-level resistance to mecillinam produced by inactivation of soluble lytic transglycosylase in Salmonella enterica serovar Typhimurium. FEMS Microbiol Lett 256:311–317. doi:10.1111/j.1574-6968.2006.00133.x.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Hancock RE
    . 1998. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 27(Suppl 1):S93–S99. doi:10.1086/514909.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Hancock RE,
    2. Brinkman FS
    . 2002. Function of pseudomonas porins in uptake and efflux. Annu Rev Microbiol 56:17–38. doi:10.1146/annurev.micro.56.012302.160310.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Trias J,
    2. Nikaido H
    . 1990. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34:52–57. doi:10.1128/aac.34.1.52.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Shu JC,
    2. Kuo AJ,
    3. Su LH,
    4. Liu TP,
    5. Lee MH,
    6. Su IN,
    7. Wu TL
    . 2017. Development of carbapenem resistance in Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly the amino acid substitution at codon 170. J Antimicrob Chemother 72:2489–2495. doi:10.1093/jac/dkx158.
    OpenUrlCrossRef
  53. 53.↵
    1. Pirnay JP,
    2. De Vos D,
    3. Mossialos D,
    4. Vanderkelen A,
    5. Cornelis P,
    6. Zizi M
    . 2002. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ Microbiol 4:872–882. doi:10.1046/j.1462-2920.2002.00281.x.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Gutierrez O,
    2. Juan C,
    3. Cercenado E,
    4. Navarro F,
    5. Bouza E,
    6. Coll P,
    7. Perez JL,
    8. Oliver A
    . 2007. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother 51:4329–4335. doi:10.1128/AAC.00810-07.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Kao CY,
    2. Chen SS,
    3. Hung KH,
    4. Wu HM,
    5. Hsueh PR,
    6. Yan JJ,
    7. Wu JJ
    . 2016. Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infections in Taiwan. BMC Microbiol 16:107. doi:10.1186/s12866-016-0719-2.
    OpenUrlCrossRef
  56. 56.↵
    1. Courtois N,
    2. Caspar Y,
    3. Maurin M
    . 2018. Phenotypic and genetic resistance traits of Pseudomonas aeruginosa strains infecting cystic fibrosis patients: a French cohort study. Int J Antimicrob Agents 52:358–364. doi:10.1016/j.ijantimicag.2018.05.008.
    OpenUrlCrossRef
  57. 57.↵
    1. Perron K,
    2. Caille O,
    3. Rossier C,
    4. Van Delden C,
    5. Dumas J-L,
    6. Köhler T
    . 2004. CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J Biol Chem 279:8761–8768. doi:10.1074/jbc.M312080200.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Caille O,
    2. Rossier C,
    3. Perron K
    . 2007. A copper-activated two-component system interacts with zinc and imipenem resistance in Pseudomonas aeruginosa. J Bacteriol 189:4561–4568. doi:10.1128/JB.00095-07.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Chen YT,
    2. Chang HY,
    3. Lu CL,
    4. Peng HL
    . 2004. Evolutionary analysis of the two-component systems in Pseudomonas aeruginosa PAO1. J Mol Evol 59:725–737. doi:10.1007/s00239-004-2663-2.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Macfarlane EL,
    2. Kwasnicka A,
    3. Ochs MM,
    4. Hancock RE
    . 1999. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol Microbiol 34:305–316. doi:10.1046/j.1365-2958.1999.01600.x.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Macfarlane EL,
    2. Kwasnicka A,
    3. Hancock RE
    . 2000. Role of Pseudomonas aeruginosa PhoP-phoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146:2543–2554. doi:10.1099/00221287-146-10-2543.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    1. Gooderham WJ,
    2. Hancock RE
    . 2009. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 33:279–294. doi:10.1111/j.1574-6976.2008.00135.x.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Barrow K,
    2. Kwon DH
    . 2009. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:5150–5154. doi:10.1128/AAC.00893-09.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Miller AK,
    2. Brannon MK,
    3. Stevens L,
    4. Johansen HK,
    5. Selgrade SE,
    6. Miller SI,
    7. Hoiby N,
    8. Moskowitz SM
    . 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 55:5761–5769. doi:10.1128/AAC.05391-11.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Li H,
    2. Durbin R
    . 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760. doi:10.1093/bioinformatics/btp324.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. McKenna A,
    2. Hanna M,
    3. Banks E,
    4. Sivachenko A,
    5. Cibulskis K,
    6. Kernytsky A,
    7. Garimella K,
    8. Altshuler D,
    9. Gabriel S,
    10. Daly M,
    11. DePristo MA
    . 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303. doi:10.1101/gr.107524.110.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Pyne ME,
    2. Moo-Young M,
    3. Chung DA,
    4. Chou CP
    . 2015. Coupling the CRISPR/Cas9 system with lambda red recombineering enables simplified chromosomal gene replacement in Escherichia coli. Appl Environ Microbiol 81:5103–5114. doi:10.1128/AEM.01248-15.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Sukhija K,
    2. Pyne M,
    3. Ali S,
    4. Orr V,
    5. Abedi D,
    6. Moo-Young M,
    7. Chou CP
    . 2012. Developing an extended genomic engineering approach based on recombineering to knock-in heterologous genes to Escherichia coli genome. Mol Biotechnol 51:109–118. doi:10.1007/s12033-011-9442-2.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Chemogenomic Screen for Imipenem Resistance in Gram-Negative Bacteria
Jessica Y. El Khoury, Alexandra Maure, Hélène Gingras, Philippe Leprohon, Marc Ouellette
mSystems Nov 2019, 4 (6) e00465-19; DOI: 10.1128/mSystems.00465-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mSystems article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Chemogenomic Screen for Imipenem Resistance in Gram-Negative Bacteria
(Your Name) has forwarded a page to you from mSystems
(Your Name) thought you would be interested in this article in mSystems.
Share
Chemogenomic Screen for Imipenem Resistance in Gram-Negative Bacteria
Jessica Y. El Khoury, Alexandra Maure, Hélène Gingras, Philippe Leprohon, Marc Ouellette
mSystems Nov 2019, 4 (6) e00465-19; DOI: 10.1128/mSystems.00465-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

chemical mutagenesis
carbapenem resistance
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa

Related Articles

Cited By...

About

  • About mSystems
  • Author Videos
  • Board of Editors
  • Policies
  • Overleaf Pilot
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Types of Articles
  • Getting Started
  • Ethics
  • Contact Us

Follow #mSystemsJ

@ASMicrobiology

       

 

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2379-5077